E-mail lunthesis@163.com Phone 0551-65179860-203

Sino-Indonesian trade benefits region, world

Pub Date:22-11-16 09:49 Source:China Daily

A visitor takes a selfie at an automobile exhibition showcasing vehicles made by Chinese manufacturer Dongfeng Xiaokang in Tangerang, Indonesia, in August. [Photo/XINHUA]

Closer China-Indonesia economic and trade cooperation will benefit the two countries and add new growth momentum to the regional and world economy, experts and business leaders said, adding that the two populous developing countries share huge trade complementarity, entwined interests and great economic cooperation potential.

Since Julong Group, whose headquarters are in Tianjin, started operations in Indonesia in 2006, it has established oil palm plantations covering nearly 66,700 hectares. It also operates four palm oil factories, two palm kernel crushing plants, one packaging factory and eight river ports in the Southeast Asian country.

Palm oil and other products in its seven factories are forecast to have a total value of 1.6 billion yuan ($230 million) this year. Of that, palm kernel oil and meal worth 300 million yuan are expected to be exported to China, and the rest will be sold on the Indonesian market, said Lei Wenzhong, CEO of the company's Indonesian branch.

According to China's Ministry of Foreign Affairs, China and Indonesia's bilateral trade surged to $124.43 billion in 2021, increasing nearly 60 percent on a yearly basis.

Indonesia was also China's second-largest outbound investment destination in the Association of Southeast Asian Nations last year.

"Thanks to the stronger bilateral ties between China and Indonesia, confidence of Chinese investors in Indonesia is growing, which in turn adds impetus to the economic and trade cooperation between the two countries," Lei said.

As the world's fourth-most-populous country, Indonesia has not only rich resources but also a huge market for Chinese enterprises to tap mutually beneficial investment and trade cooperation, he added.

Xu Ningning, executive president of the China-ASEAN Business Council, said cooperation between the two countries has provided valuable wisdom for not only the region but also the world to cope with the ongoing challenges and complexities.

Indonesia ratified the Regional Comprehensive Economic Partnership agreement on Aug 30 and the agreement will take effect in the country within the year. According to Xu, that will enable the country to receive more investment in downstream industries, particularly in the commodity processing sector.

The RCEP took effect on Jan 1, creating the world's largest free trade bloc.

Zhou Mi, a senior researcher at the Chinese Academy of International Trade and Economic Cooperation in Beijing, said China and Indonesia have huge cooperation potential in industrial and supply chain coordination, infrastructure construction and e-commerce development, as they have differentiated supply and demand advantages.

Experts also said the two need to further deepen Belt and Road cooperation and ensure good implementation of major cooperation projects — for example with the high-standard construction of the Jakarta-Bandung high-speed railway — and to step up cooperation in the health and pharmaceutical industry.

Chinese vaccine maker Sinovac Biotech said Indonesia was one of the first countries to approve its COVID-19 vaccine, and the company has been supporting large-scale vaccination programs in Indonesia since then.

It has provided more than 280 million doses of COVID-19 vaccines to Indonesia, more than 130 million doses of which were exported as bulk vaccine to be locally processed and packaged.

China's Abogen Biosciences said it plans to build a joint venture in Indonesia with the Indonesian biotech company Etana to tap the country's pharmaceutical market and accelerate its going-global strategy while at the same time helping Indonesia upgrade its biomedicine industry.

The company has already transferred the manufacturing technology of its mRNA COVID-19 vaccine to Etana. That makes Indonesia one of the few countries able to develop high-end pharmaceutical products via the mRNA technology.


Related News
6G push picks up speed with focus on innov...
GLOBALink | Chinese-invested industrial pa...
China rolls out plan to improve business e...
Economic Watch: Multinationals' earnings r...
Contact Us
Copyright ©2000-2021 anhuinews.com All rights reserved. Reproduction in whole or in part without permission is prohibited. 皖B2-20080023-7